The US Centers for Medicare and Medicaid Services has taken a step toward implementing one of the policies in the Trump Administration’s drug price reduction blueprint by proposing to lower short-term Medicare payments for certain new physician-administered drugs reimbursed under Part B.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?